piracetam has been researched along with Mood Disorders in 9 studies
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.
Mood Disorders: Those disorders that have a disturbance in mood as their predominant feature.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This report reviews behavioral adverse events occurring among adults receiving levetiracetam (LEV) or placebo who participated in short-term, placebo-controlled studies in epilepsy (1023), cognitive disorders (719), or anxiety disorders (1510) and epilepsy patients (1393) observed in long-term trials." | 8.82 | A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. ( Cramer, JA; De Rue, K; Devinsky, O; Edrich, P; Trimble, MR, 2003) |
| "Levetiracetam is a newer antiepileptic agent that was first approved by the US FDA in 1999 as an adjunctive therapy for the treatment of refractory partial epilepsy in adults." | 6.43 | Potential of levetiracetam in mood disorders: a preliminary review. ( Bhagwagar, Z; Muralidharan, A, 2006) |
| "In this postlicensing surveillance study in a large unselected population, data were collected prospectively on all patients prescribed levetiracetam (LEV) at a regional epilepsy clinic over a 2-year period." | 5.11 | A prospective analysis of the outcome of levetiracetam in clinical practice. ( Lewis, SA; Nicolson, A; Smith, DF, 2004) |
| " We tested this hypothesis by reviewing the multiple mechanisms of action of topiramate (TPM) and levetiracetam (LEV) together with clinical behavioral side effects of patients who had been treated with TPM and LEV in a tertiary referral center for epilepsy." | 5.11 | Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam. ( Aldenkamp, AP; Bootsma, HP; Kessels, AG; Leenen, LA; Leonard, BE; Majoie, HJ; Roberts, GM, 2005) |
| "This report reviews behavioral adverse events occurring among adults receiving levetiracetam (LEV) or placebo who participated in short-term, placebo-controlled studies in epilepsy (1023), cognitive disorders (719), or anxiety disorders (1510) and epilepsy patients (1393) observed in long-term trials." | 4.82 | A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials. ( Cramer, JA; De Rue, K; Devinsky, O; Edrich, P; Trimble, MR, 2003) |
| "Levetiracetam is a newer antiepileptic agent that was first approved by the US FDA in 1999 as an adjunctive therapy for the treatment of refractory partial epilepsy in adults." | 2.43 | Potential of levetiracetam in mood disorders: a preliminary review. ( Bhagwagar, Z; Muralidharan, A, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (66.67) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Taneja, R | 1 |
| Hunter, K | 1 |
| Burakgazi-Dalkilic, E | 1 |
| Carran, M | 1 |
| de la Loge, C | 1 |
| Hunter, SJ | 1 |
| Schiemann, J | 1 |
| Yang, H | 1 |
| Vorob'eva, OV | 1 |
| Tamarova, ES | 1 |
| Cramer, JA | 1 |
| De Rue, K | 1 |
| Devinsky, O | 1 |
| Edrich, P | 1 |
| Trimble, MR | 1 |
| Nicolson, A | 1 |
| Lewis, SA | 1 |
| Smith, DF | 1 |
| Roberts, GM | 1 |
| Majoie, HJ | 1 |
| Leenen, LA | 1 |
| Bootsma, HP | 1 |
| Kessels, AG | 1 |
| Aldenkamp, AP | 1 |
| Leonard, BE | 1 |
| Stoner, SC | 1 |
| Lea, JW | 1 |
| Wolf, AL | 1 |
| Berges, AA | 1 |
| Muralidharan, A | 1 |
| Bhagwagar, Z | 1 |
| Mula, M | 1 |
| Sander, JW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20 - 60 mg/kg/Day, Divided in Twice Daily Dosing, as Adjunctive Treatment in Children 4 - 16 Years [NCT00105040] | Phase 2 | 87 participants (Actual) | Interventional | 2004-09-30 | Completed | ||
| Levetiracetam in the Management of Bipolar Depression[NCT00566150] | 35 participants (Actual) | Interventional | 2005-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Change is observed value at each visit minus baseline value. CGI-BP depression severity is an instrument which measures severity of depression in bipolar disorder. Scale range: 1=normal, not ill; 7=very severely ill (NCT00566150)
Timeframe: Baseline to week 6
| Intervention | score on scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=17, n=15) | Week 2 (n=14, n=14) | Week 3 (n=13, n=14) | Week 4 (n=11, n=13) | Week 5 (n=11, n=12) | Week 6 (n=10, n=10) | |
| Levetiracetam | -0.2941 | -0.3186 | -0.1984 | -0.3729 | -0.7325 | -0.5742 |
| Placebo | -0.4667 | -0.6956 | -0.7753 | -0.8403 | -0.8739 | -0.9294 |
Change is observed value at each visit minus baseline value. HDRS-21 is a 21-item instrument measuring depression. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 60. (NCT00566150)
Timeframe: Baseline to week 6
| Intervention | score on scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=17, n=15) | Week 2 (n=15, n=14) | Week 3 (n=13, n=14) | Week 4 (n=11, n=13) | Week 5 (n=11, n=13) | Week 6 (n=10, n=11) | |
| Levetiracetam | -2.7647 | -3.4259 | -2.1243 | -4.3534 | -6.952 | -4.8136 |
| Placebo | -4 | -6.5875 | -6.3625 | -6.3851 | -6.4368 | -7.0712 |
Change is observed value at each visit minus baseline value. MADRS is a 10-item instrument measuring depression: scale range between 0(normal) - 6(most abnormal)for each item. Total possible score is 0 - 60. (NCT00566150)
Timeframe: Baseline to week 6
| Intervention | score on scale (Least Squares Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=17, n=15) | Week 2 (n=15, n=14) | Week 3 (n=13, n=14) | Week 4 (n=11, n=13) | Week 5 (n=11, n=12) | Week 6 (n=10, n=11) | |
| Levetiracetam | -3.2941 | -5.2319 | -3.384 | -5.5505 | -9.9142 | -6.5208 |
| Placebo | -2.7333 | -7.256 | -9.0417 | -8.7608 | -6.6591 | -4.5153 |
"Remission response is measured as an HDRS-21 total score is less than or equal to 7.~HDRS-21 measures range of depressive symptoms. Endpoint is LOCF." (NCT00566150)
Timeframe: Week 6
| Intervention | Participants (Number) | |
|---|---|---|
| Remitted | Not remitted | |
| Levetiracetam | 0 | 17 |
| Placebo | 4 | 11 |
2 reviews available for piracetam and Mood Disorders
| Article | Year |
|---|---|
A systematic review of the behavioral effects of levetiracetam in adults with epilepsy, cognitive disorders, or an anxiety disorder during clinical trials.
Topics: Anticonvulsants; Anxiety Disorders; Cognition Disorders; Cross-Over Studies; Double-Blind Method; Dr | 2003 |
Potential of levetiracetam in mood disorders: a preliminary review.
Topics: Animals; Anticonvulsants; Clinical Trials as Topic; Humans; Levetiracetam; Mood Disorders; Piracetam | 2006 |
4 trials available for piracetam and Mood Disorders
| Article | Year |
|---|---|
Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial.
Topics: Adolescent; Anticonvulsants; Behavioral Symptoms; Checklist; Child; Child, Preschool; Double-Blind M | 2010 |
[Efficacy of vinpotropile in the therapy of initial signs of cerebrovascular pathology].
Topics: Aged; Brain Ischemia; Cognition Disorders; Drug Combinations; Female; Humans; Male; Middle Aged; Moo | 2010 |
A prospective analysis of the outcome of levetiracetam in clinical practice.
Topics: Anticonvulsants; Consciousness Disorders; Drug Administration Schedule; Drug Resistance; Drug Therap | 2004 |
Ketter's hypothesis of the mood effects of antiepileptic drugs coupled to the mechanism of action of topiramate and levetiracetam.
Topics: Adult; Anticonvulsants; Chi-Square Distribution; Demography; Drug Therapy, Combination; Epilepsy; Fe | 2005 |
3 other studies available for piracetam and Mood Disorders
| Article | Year |
|---|---|
Effect of sleep patterns on levetiracetam induced mood changes.
Topics: Adult; Analysis of Variance; Anticonvulsants; Anxiety Disorders; Circadian Rhythm; Depressive Disord | 2017 |
Levetiracetam for mood stabilization and maintenance of seizure control following multiple treatment failures.
Topics: Anticonvulsants; Carbamazepine; Drug Therapy, Combination; Female; Fructose; Humans; Levetiracetam; | 2005 |
Suicidal ideation in epilepsy and levetiracetam therapy.
Topics: Adult; Affective Symptoms; Anticonvulsants; Epilepsy; Female; Humans; Levetiracetam; Male; Mood Diso | 2007 |